Skip to content

Which is the better treatment for lung metastases from giant cell tumor of bone, metastasectomy or non-metastasectomy? A systematic review

Which is the better treatment for lung metastases from giant cell tumor of bone, metastasectomy or non-metastasectomy? A systematic review - Lung metastases from GCTB: A systematic review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000038826
Enrollment
100
Registered
2019-12-09
Start date
2019-12-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung metastases from giant cell tumor of bone

Interventions

None listed

Sponsors

Nara Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All comparative reports examining tumor-related death in patients who had giant cell tumors of bone and operable lung metastases and were treated with metastasectomy and non-metastasectomy, were included. Metastasectomy group included patients treated with metastasectomy alone, metastasectomy and chemotherapy, metastasectomy and radiotherapy, and metastasectomy, chemotherapy and radiotherapy.Non-metastasectomy group included patients treated with observation alone, chemotherapy alone, and chemotherapy and radiotherapy.We included human studies and articles with clearly-described death following treatment for lung metastases. We counted only tumor-related death, and excluded the death unrelated to disease and the death related to chemotherapy.

Exclusion criteria

Exclusion criteria: The patients who had inoperable lung metastases and were treated with observation, chemotherapy, or radiotherapy, were excluded.We excluded studies without a comparison group, those without a report of tumor-related death, isolated case reports or case series including fewer than five patients and non-English and non-Japanese language abstracts. We did not place any restrictions on the date of publication.

Design outcomes

Primary

MeasureTime frame
We counted only tumor-related death as the outcome, and excluded the death unrelated to disease and the death related to chemotherapy.

Countries

Japan,Europe

Contacts

Public ContactShinji Tsukamoto

Nara Medical University Department of Orthopaedic Surgery

shinji104@mail.goo.ne.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026